Analysis for MCK

📈 Growth & Financial Trajectory

Over 8 quarters, McKesson's revenue scaled from about $79.3B (2024 Q4) to about $96.3B (2026 Q4), roughly a +21% expansion. Net income rose from about $0.8B to around $1.9B, though quarterly results fluctuated, with mid-2025 variance before resuming an uptrend. The trajectory shows meaningful scale with some volatility, rather than a rapid margin-driven acceleration.

💰 Margins & Cash Flow

Gross margins hovered near 3.5%–4.5%, indicating limited operating leverage. Operating income generally lived in the $1.0B–$2.2B band, yielding modest margins. Cash flow from operations has been uneven but recently positive, with the latest quarter showing net cash flow around $1.02B. Investing activity was typically negative, and financing activity movements amplified cash-flow volatility; overall cash performance remains sensitive to working capital and financing swings.

🛡️ Balance Sheet & Liquidity

Total assets run around $84B and liabilities near $84B–$85B, with reported equity near -$2B in multiple periods. Current assets ~$57B–$60B and current liabilities ~$68B–$67B, implying a current ratio around 0.85–1.0. This signals solvency pressures and liquidity tightness despite a solid asset base and ongoing cash generation.

⚠️ Key Drivers & Risks

• Drivers: Healthcare distribution scale, robust procurement networks, and demand for pharmaceutical/medical supplies.
• Risks: Regulatory/regulatory-change exposure, cyclicality in healthcare demand, and valuation sensitivity given persistent negative equity and liquidity constraints.